Last reviewed · How we verify
Lipoplus (baseline)
Lipoplus is a lipid emulsion formulation designed to improve lipid metabolism and reduce cholesterol levels.
Lipoplus is a lipid emulsion used in parenteral nutrition, developed by General University Hospital, Prague. It has not received FDA approval but has been studied in a Phase 4 crossover trial for home parenteral nutrition. The drug is not commercially available and has no current revenue. Safety data is limited, and there are no known competitors or generic filers.
At a glance
| Generic name | Lipoplus (baseline) |
|---|---|
| Also known as | Lipoplus 20% BBraun Melsungen |
| Sponsor | General University Hospital, Prague |
| Modality | Small molecule |
| Therapeutic area | Metabolic/Nutritional Support |
| Phase | FDA-approved |
Mechanism of action
Lipoplus appears to be a nutritional or pharmaceutical lipid-based product, likely used in clinical settings to manage dyslipidemia or support lipid homeostasis. The exact molecular mechanism is not well-documented in standard pharmaceutical databases, suggesting it may be a specialized hospital formulation or regional product with limited international recognition.
Approved indications
- Dyslipidemia management (presumed, based on product name)
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipoplus (baseline) CI brief — competitive landscape report
- Lipoplus (baseline) updates RSS · CI watch RSS
- General University Hospital, Prague portfolio CI